Top
CD30-Expressing Lymphomas - Healing Genes
1332
post-template-default,single,single-post,postid-1332,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

CD30-Expressing Lymphomas

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas


Phase 2

DESCRIPTION:
Doctors at the National Institutes of Health Clinical Center in Bethesda, MD, seek patients with lymphomas (including Large-Cell, Anaplastic, Hodgkin Disease, Lymphoma, Hodgkins Enteropathy-Associated T-Cell Lymphoma, Extranodal NK-T-Cell Lymphoma) that express CD-30 antigen to trial a therapeutic gene therapy. This therapy utilizes the patient’s own (autologous) stem cells, drawn from bone marrow and blood, which will be gene-modified in the lab to impart a gene for the CD-30 immune receptor which targets cancer cells. After chemotherapy to reduce the existing immune system, these modified cells are re-infused, intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer.

Follow up will continue for 5 years.


PATIENT MUST:

  • Be 18 to 73 years of age
  • Have confirmation of diagnosis of an approved cancer meeting the study’s clinical guidelines
  • Meet lab criteria to confirm their cancer expresses the antigen to which the study plans to gene-modify cells to recognize

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Blood draw to recover the patient’s own T-cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
  3. Admission to the study center and a course of chemotherapy.
  4. Infusion of the gene-modified T-cells.
  5. Blood collection for safety and immune monitoring for 4 to 5 weeks, then long-term follow up for 5 years.

LOCATIONS & CONTACTS:
Trials will take place at the National Institutes of Health Clinical Center in Bethesda, MD. Map.

Contact:
Brenna Hansen  |  (240) 760-6168  |  [email protected]
 
SPONSORS
National Cancer Institute (NCI)
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03049449

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader